Abstract
Direct inhibitors of coagulation factor Xa (FXa) or thrombin are promising oral anticoagulants that are becoming widely adopted. The ability to reverse their anticoagulant effects is important when serious bleeding occurs or urgent medical procedures are needed. Here, using experimental mouse models of hemostasis, we show that a variant coagulation factor, FXaI16L, rapidly restores hemostasis in the presence of the anticoagulant effects of these inhibitors. The ability of FXaI16L to reverse the anticoagulant effects of FXa inhibitor depends, at least in part, on the ability of the active site inhibitor to hinder antithrombin-dependent FXa inactivation, paradoxically allowing uninhibited FXa to persist in plasma. Because of its inherent catalytic activity, FXaI16L is more potent (by >50-fold) in the hemostasis models tested than a noncatalytic antidote that is currently in clinical development. FXaI16L also reduces the anticoagulant-associated bleeding in vivo that is induced by the thrombin inhibitor dabigatran. FXaI16L may be able to fill an important unmet clinical need for a rapid, pro-hemostatic agent to reverse the effects of several new anticoagulants.
Similar content being viewed by others
References
Ansell, J. et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133, 160S–198S (2008).
Yeh, C.H., Hogg, K. & Weitz, J.I. Overview of the new oral anticoagulants: opportunities and challenges. Arterioscler. Thromb. Vasc. Biol. 35, 1056–1065 (2015).
Perzborn, E. et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitor. J. Thromb. Haemost. 3, 514–521 (2005).
Pinto, D.J. et al. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious and orally bioavailable inhibitor of blood coagulation factor Xa. J. Med. Chem. 50, 5339–5356 (2007).
Furugohri, T. et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J. Thromb. Haemost. 6, 1542–1549 (2008).
Di Nisio, M., Middeldorp, S. & Büller, H.R. Direct thrombin inhibitors. N. Engl. J. Med. 353, 1028–1040 (2005).
Büller, H.R. et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N. Engl. J. Med. 369, 1406–1415 (2013).
Granger, C.B. et al. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365, 981–992 (2011).
Lassen, M.R. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N. Engl. J. Med. 358, 2776–2786 (2008).
Connolly, S.J. et al. Apixaban in patients with atrial fibrillation. N. Engl. J. Med. 364, 806–817 (2011).
Connolly, S.J. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361, 1139–1151 (2009).
Bauersachs, R. et al. Oral rivaroxaban for symptomatic venous thromboembolism. N. Engl. J. Med. 363, 2499–2510 (2010).
Dentali, F. et al. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation 126, 2381–2391 (2012).
Fox, B.D., Kahn, S.R., Langleben, D., Eisenberg, M.J. & Shimony, A. Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomized controlled trials. Br. Med. J. 345, e7498 (2012).
Siegal, D.M. & Cuker, A. Reversal of target-specific oral anticoagulants. Drug Discov. Today 19, 1465–1470 (2014).
Crowther, M. & Crowther, M.A. Antidotes for novel oral anticoagulants: current status and future potential. Arterioscler. Thromb. Vasc. Biol. 35, 1736–1745 (2015).
Ansell, J.E. Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants. J. Thromb. Thrombolysis 41, 248–252 (2016).
Husted, S., Verheugt, F.W. & Comuth, W.J. Reversal strategies for NOACs: state of development, possible clinical applications and future perspectives. Drug Saf. 39, 5–13 (2016).
Schiele, F. et al. A specific antidote for dabigatran: functional and structural characterization. Blood 121, 3554–3562 (2013).
Glund, S. et al. Safety, tolerability and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomized, placebo-controlled, double-blind phase 1 trial. Lancet 386, 680–690 (2015).
Lu, G. et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat. Med. 19, 446–451 (2013).
Ansell, J.E. et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N. Engl. J. Med. 371, 2141–2142 (2014).
Eerenberg, E.S. et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124, 1573–1579 (2011).
Perzborn, E., Heitmeier, S., Laux, V. & Buchmüller, A. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro. Thromb. Res. 133, 671–681 (2014).
Herrmann, R. et al. Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban. Thromb. Haemost. 111, 989–995 (2014).
Perzborn, E. et al. Reversal of rivaroxaban anticoagulation by hemostatic agents in rats and primates. Thromb. Haemost. 110, 162–172 (2013).
Godier, A. et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 116, 94–102 (2012).
Vandana, M. et al. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for FXa inhibitors. Blood 122, 3636–3636 (2013).
Siegal, D.M. et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N. Engl. J. Med. 373, 2413–2424 (2015).
Bajaj, M.S., Birktoft, J.J., Steer, S.A. & Bajaj, S.P. Structure and biology of tissue factor pathway inhibitor. Thromb. Haemost. 86, 959–972 (2001).
Huntington, J.A. Thrombin inhibition by the serpins. J. Thromb. Haemost. 11 (suppl. 1), 254–264 (2013).
Toso, R., Zhu, H. & Camire, R.M. The conformational switch from the factor X zymogen to protease state mediates exosite expression and prothrombinase assembly. J. Biol. Chem. 283, 18627–18635 (2008).
Bunce, M.W., Toso, R. & Camire, R.M. Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro. Blood 117, 290–298 (2011).
Ivanciu, L. et al. A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia. Nat. Biotechnol. 29, 1028–1033 (2011).
Bode, W. et al. The refined 1.9 Å crystal structure of human α-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J. 8, 3467–3475 (1989).
Samama, M.M. et al. Laboratory assessment of rivaroxaban: a review. Thromb. J. 11, 11 (2013).
Samama, M.M. & Guinet, C. Laboratory assessment of new anticoagulants. Clin. Chem. Lab. Med. 49, 761–772 (2011).
Mueck, W., Stampfuss, J., Kubitza, D. & Becka, M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin. Pharmacokinet. 53, 1–16 (2014).
Turecek, P.L., Váradi, K., Gritsch, H. & Schwarz, H.P. FEIBA: mode of action. Haemophilia 10 (suppl. 2), 3–9 (2004).
Whinna, H.C. Overview of murine thrombosis models. Thromb. Res. 122 (suppl. 1), S64–S69 (2008).
Scaglione, F. New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin. Pharmacokinet. 52, 69–82 (2013).
Gitel, S.N., Medina, V.M. & Wessler, S. Inhibition of human activated Factor X by antithrombin III and α1-proteinase inhibitor in human plasma. J. Biol. Chem. 259, 6890–6895 (1984).
Olson, S.T. et al. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin–proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J. Biol. Chem. 267, 12528–12538 (1992).
Conard, J., Brosstad, F., Lie Larsen, M., Samama, M. & Abildgaard, U. Molar antithrombin concentration in normal human plasma. Haemostasis 13, 363–368 (1983).
Izaguirre, G. et al. Conformational activation of antithrombin by heparin involves an altered exosite interaction with protease. J. Biol. Chem. 289, 34049–34064 (2014).
Perzborn, E. et al. Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler. Thromb. Vasc. Biol. 30, 376–381 (2010).
Craig, P.A., Olson, S.T. & Shore, J.D. Transient kinetics of heparin-catalyzed protease inactivation by antithrombin III. Characterization of assembly, product formation and heparin dissociation steps in the factor Xa reaction. J. Biol. Chem. 264, 5452–5461 (1989).
Olson, S.T. & Shore, J.D. Transient kinetics of heparin-catalyzed protease inactivation by antithrombin III. The reaction step limiting heparin turnover in thrombin neutralization. J. Biol. Chem. 261, 13151–13159 (1986).
Esmon, C.T. & Owen, W.G. The discovery of thrombomodulin. J. Thromb. Haemost. 2, 209–213 (2004).
Smith, S.A. & Morrissey, J.H. Polyphosphate as a general procoagulant agent. J. Thromb. Haemost. 6, 1750–1756 (2008).
Weiler-Guettler, H. et al. A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J. Clin. Invest. 101, 19 83–1991 (1998).
Neyman, M., Gewirtz, J. & Poncz, M. Analysis of the spatial and temporal characteristics of platelet-delivered factor-VIII-based clots. Blood 112, 1101–1108 (2008).
Kisiel, W., Hermodson, M.A. & Davie, E.W. Factor X activating enzyme from Russell's viper venom: isolation and characterization. Biochemistry 15, 4901–4906 (1976).
Larson, P.J. et al. Structure–function analyses of recombinant variants of human factor Xa: factor Xa incorporation into prothrombinase on the thrombin-activated platelet surface is not mimicked by synthetic phospholipid vesicles. Biochemistry 37, 5029–5038 (1998).
Camire, R.M., Larson, P.J., Stafford, D.W. & High, K.A. Enhanced γ-carboxylation of recombinant factor X using a chimeric construct containing the prothrombin propeptide. Biochemistry 39, 14322–14329 (2000).
Morita, T. & Jackson, C.M. Preparation and properties of derivatives of bovine factor X and factor Xa from which the γ-carboxyglutamic-acid-containing domain has been removed. J. Biol. Chem. 261, 4015–4023 (1986).
Toso, R. & Camire, R.M. Removal of B-domain sequences from factor V rather than specific proteolysis underlies the mechanism by which cofactor function is realized. J. Biol. Chem. 279, 21643–21650 (2004).
Lu, G., Broze, G.J. Jr. & Krishnaswamy, S. Formation of factors IXa and Xa by the extrinsic pathway: differential regulation by tissue factor pathway inhibitor and antithrombin III. J. Biol. Chem. 279, 17241–17249 (2004).
Parry, T.J. et al. Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis. Blood Coagul. Fibrinolysis 22, 720–726 (2011).
Falati, S., Gross, P., Merrill-Skoloff, G., Furie, B.C. & Furie, B. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat. Med. 8, 1175–1181 (2002).
Schlachterman, A. et al. Factor V Leiden improves in vivo hemostasis in murine hemophilia models. J. Thromb. Haemost. 3, 2730–2737 (2005).
Lin, H.F., Maeda, N., Smithies, O., Straight, D.L. & Stafford, D.W. A coagulation factor IX–deficient mouse model for human hemophilia B. Blood 90, 3962–3966 (1997).
Ivanciu, L., Krishnaswamy, S. & Camire, R.M. New insights into the spatiotemporal localization of prothrombinase in vivo. Blood 124, 1705–1714 (2014).
Green, R.A., LaFollette, K.A. & Greig, B. Use of hexadimethrine bromide as a heparin-neutralizing agent in canine plasma. Am. J. Vet. Res. 48, 496–498 (1987).
Acknowledgements
This work was supported in part by the US National Institutes of Health (NIH) grants F30 HL-120487 (N.K.T.), T32 HL-007439 (N.K.T.), T32 GM-007170 (N.K.T.) and P01 HL-74124 (R.M.C. and S.K.), the Penn–CHOP Blood Center for Patient Care and Discovery (P.A.G.) and research funding from Pfizer (R.M.C.). We are grateful to V. Arruda (Children's Hospital of Philadelphia and University of Pennsylvania) and L. Brass (University of Pennsylvania) for useful suggestions and critical review of the manuscript.
Author information
Authors and Affiliations
Contributions
N.K.T. designed, coordinated and performed experiments; L.I. and R.D. designed and performed experiments; N.K.T., S.K. and R.M.C. designed experiments and analyzed data; P.A.G. analyzed data; and N.K.T., L.I., S.K. and R.M.C. wrote the paper. All authors discussed the results and commented on the manuscript.
Corresponding author
Ethics declarations
Competing interests
R.M.C. receives licensing fees and research funding from Pfizer for work related to FXaI16L.
Supplementary information
Supplementary Text and Figures
Supplementary Tables 1–4 and Supplementary Figures 1–11 (PDF 5514 kb)
Rights and permissions
About this article
Cite this article
Thalji, N., Ivanciu, L., Davidson, R. et al. A rapid pro-hemostatic approach to overcome direct oral anticoagulants. Nat Med 22, 924–932 (2016). https://doi.org/10.1038/nm.4149
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.4149
- Springer Nature America, Inc.
This article is cited by
-
Blood coagulation factor X: molecular biology, inherited disease, and engineered therapeutics
Journal of Thrombosis and Thrombolysis (2021)
-
Deciphering the coagulation profile through the dynamics of thrombin activity
Scientific Reports (2020)
-
The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review
International Journal of Emergency Medicine (2018)
-
Combination of aptamer and drug for reversible anticoagulation in cardiopulmonary bypass
Nature Biotechnology (2018)
-
Blutungen unter direkten oralen Antikoagulanzien
Medizinische Klinik - Intensivmedizin und Notfallmedizin (2018)